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Abstract Pneumonia is a significant medical complication fol-
lowing aneurysmal subarachnoid hemorrhage (aSAH). The
aSAH may initiate immune interactions leading to depressed
immunofunction, followed by an increased risk of infection. It
remains unclear as to whether there is a possible association
between cerebral metabolism and infections. Clinical and mi-
crodialysis data from aSAH patients prospectively included in
the CoOperative Study on Brain Injury Depolarisations protocol
Berlin were analyzed. Levels of glucose, lactate, pyruvate, and
glutamate were measured hourly using microdialysis in the
cerebral extracellular fluid. The occurrence of pneumonia (de-
fined by positivemicrobiological cultures) and delayed ischemic
neurological deficits (DIND) was documented prospectively.
Eighteen aSAH patients (52.7±10.7 years), classified according
to the World Federation of Neurological Surgeons in low (I–III,
n=9) and high (IV–V, n=9) grades, were studied. Eight patients
(45 %) experienced DIND, 10 patients (56 %) pneumonia
(mean onset day 2.6). Lactate was elevated at day 3 in infected
patients (n=9, median=6.82 mmol/L) vs. patient without infec-
tions (n =6, median=2.90 mmol/L, p=0.036). The optimum
cut-off point to predict pneumonia at day 3 was 3.57 mmol/L
with a sensitivity of 0.77, and a specificity of 0.66 (area under
curve was 0.833 with p=0.034). Lactate at day 7 was higher in
DIND patients compared to no-DIND-patients (p=0.016). Ear-
ly elevated lactate correlated with occurrence of bacterial pneu-
monia, while late elevations with DIND after aSAH. Future
investigations may elucidate the relationship between cerebral
lactate and markers of immunocompetence and more detailed to
identify patients with higher susceptibility for infections.
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Introduction
Cerebral lactate in extracellular fluid (ECF) is frequently high
after aneurysmal subarachnoid hemorrhage (aSAH) in pa-
tients with delayed ischemic deficits presumably due to the
presence of anaerobic glycolysis as a result of ischemia.
Furthermore, the presence of lactate in the ECF is known to
be associated with unfavorable outcome after aSAH [1]
In aSAH, pneumonia is described in 20 % of the patients
and has been associated with a threefold increased risk of
death at 30 days for stroke patients [2, 3]. Therefore, the
occurrence of systemic infection after aSAH may be a
symptom of impaired immune competence in these patients
[4–6].
There is a rising debate about the role of inflammation
for the progression of aSAH-induced secondary brain damage
and complications after SAH [7, 8]. Several studies have
confirmed the activation of the immune system with a
prominent elevation of interleukin (IL)-6, IL-1 beta, and
TNF-alpha early after aSAH [9]. Importantly, intracerebral
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IL-6 values were predictive for the development of secondary
brain injury, delayed ischemic events, and critical brain swell-
ing [10–15]. It is postulated that aSAH turns the cerebrospinal
fluid (CSF) and cerebral extracellular fluid into a pro-
inflammatory milieu [16]. The inflammatory activation of
the immune system followed by an immunodepressive
counter-reaction in aSAH patients might be an important
contributor to secondary brain injury.
Preliminary data have shown that immunodepression with
increased susceptibility for infections exist early and remains
prolonged among aSAH patients with acute focal deficits
(AFND), or delayed ischemic neurological deficit (DIND)
[6]. In these patients, a persistent suppression of the cellular
immune response as well as an impaired pro-inflammatory
cytokine release by monocytes and lymphocytes throughout
the observation period of 10 days was observed, while in
asymptomatic patients (no DIND), parameters of immune
competence recovered within 3–5 days after aSAH [6].
This study aims to explore an association between markers
of cerebral metabolism measured in brain interstitial fluid of
aSAH patients (reflecting the primary damage after SAH), and
the development of bacterial infections.
Materials and Methods
Patient Population
Between October 2010, and January 2012, 18 consecutive
aSAH patients from the university hospital of Charité Berlin
were enrolled in a prospective study on cerebral metabolism in
the CoOperative Study on Brain Injury Depolarisations pro-
tocol. The local Research Ethics Committee approved this
study in compliance with the Declaration of Helsinki. Written
informed consent was obtained from the patients or nearest
family relatives.
Clinical presentation was graded according to the World
Federation of Neurological Surgeons (WFNS) [17] and pa-
tients were categorized according to the WFNS score as low
grade (WFNS score I–III) or high grade (WFNS score IV–V)
SAH patients and the Hunt and Hess grading system [18].
Aneurysm location was assessed using four-vessel angiogra-
phy and/or CT angiography on the day of admission. The
distribution and pattern of the hemorrhage was graded as
proposed by Fisher [19]. The details and the management of
patients with aSAH in the intensive care unit have been
described elsewhere (http://www.cosbid.org).
Diagnosis of Delayed Ischemic Neurological deficits
A DIND was defined as the occurrence of focal neurological
impairment (such as hemiparesis, aphasia, apraxia, hemianopia,
or neglect) or a decrease of at least 2 points on the Glasgow
Coma Scale [either on the total score or on one of its
individual components (eye, motor on either side, verbal)]
[20–22].
Moreover, the diagnosis of a DIND required that the
neurological deficit was not present immediately after
aneurysm occlusion, lasted for at least 1 h, and could not
be attributed to other causes such as hydrocephalus or re-
bleeding by means of clinical assessment, CT or MRI of the
brain, and appropriate laboratory studies. Neuroimaging
studies were performed postoperatively, at the time of clinical
deterioration and after the monitoring period to screen for
delayed infarcts.
Bedside Microdialysis
A microdialysis catheter (CMA 70, CMA, Sweden; length
10 mm, cut-off 100 kDa) was inserted after aneurysm
clipping into brain parenchyma of the respective vascular
territory of the aneurysm. Insertion depth of the catheter tip
was approximately 15 mm from dura level. Location of the
catheter tip was controlled on postoperative CT scan. The
catheter was perfused with sterile Ringer's solution at a
flow rate of 0.3 μl/min. On the outlet tube, perfusates were
collected in microvials, exchanged hourly and stored at
−80 °C, as previously described [9]. Average median
values (12 h) were analyzed for patients with AFND,
pneumonia, and DIND. Microdialysis started within the
first 24 h after admission.
Adverse Events
Adverse events have been recorded prospectively according
to the published criteria: [23] Pneumonia : new infiltrate on
chest x-ray, with purulent sputum, and/or positive microbio-
logical cultures. Delayed ischemic neurological deficits : see
above . AFND based on the clinical course , with symptoms,
such as hemiparesis, or aphasia related to the initial hemor-
rhage with corresponding CT findings.
Data Analysis
Descriptive Statistics and Univariate Analysis
Intergroup comparisons were performed on daily assessed
values for microdialysis (MD) parameters within the first
12 days after aSAH using the Mann–Whitney U test for two
samples. Fisher's exact test was used to test for group-specific
differences in patient's characteristics. MD parameter concen-
tration was expressed as median [inter-quartile range].
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Multivariate Analysis of Variance
Performing multivariate analysis of variance (MANOVA)
allows a simultaneous comparison of the medians of lactate
levels across the dichotomized clinical groups of this study,
taking into account their co-variation—as represented by the
error variance–covariance matrix in the MANOVA model.
Because the independent clinical variables in our study com-
prises more than two groups, we focused on MANOVA using
Pillai's trace [24] since this method provides a multivariate
tests that is robust to differences among the error variance–
covariance matrices within groups, as well as to departures
from the assumption of multivariate normality [25]. In
addition, a receiver operating characteristic curve
(ROC) was constructed for levels of lactate at days with
significant different median levels to determine cut-off
values, specificity, and sensitivity. All statistical analyses
were performed with PASW Statistics release 18 (SPSS
Inc., Chicago, IL, USA). Differences were considered
statistically significant at p <0.05.
Results
Patient Characteristics
Demographic data of the 18 patients are summarized in Tables 1
und 2. Eighteen aSAH patients (52.7±10.7 years; mean ±
standard deviation) have been studied, and classified according
to the WFNS in low grade (I–III, n =9) and high grade (IV–V,
n =9). Patient groups (developing with or with no pneumonia)
were comparable for age, gender, and duration of microdialysis
monitoring. There were no differences in patient characteristics
for patients with or without DIND (data not shown).
Non-infectious and Infectious Adverse Events
after Aneurysmal SAH
Six patients (33 %) presented AFND. Eight patients (45 %)
developed DIND (onset day median=7; range=5–15)
(Fig. 1). Ten patients (56 %) suffered from early onset pneu-
monia (onset day median=2.5; range=1–4) as first infection.
Five of them developed additional infections: one with urinary
tract infection at day 13, one with meningitis/ventriculitis at
day 9, two with septicemia at days 4 and 11, and one with
sinusitis. Pathogens isolated in patients with pneumonia were
as follows: Pseudomonas aeroginosa (n =3), Klebsiella
oxytoca (n =1), Klebsiella pneumoniae (n =1), Enterobacter
aerogenes (n =1), Serratia marcescens (n =1). In three cases,
only the radiological and clinical criteria of pneumonia
were fulfilled. Nearly 90 % of the patients had been
ventilated mechanically. In this study, a relation between
ventilation and incidence of pneumonia could not be
proven. Also, the mechanical ventilation durations of pa-
tients without/with AFND and without/with DIND did not
differ significantly. Fig. 1 demonstrates the baseline
Table 1 Patient characteristics for pneumonia
All patients (n =18) No pneumonia (n =8) Pneumonia (n =10) p Value
Age 51.5 [31–77] 54 [48–62] 56 [41–63] NS
Male/female 8/10 (55/45 %) 4/4 (50/50 %) 4/6 (40/60 %) NS
Coiling/clipping 5/13 (28/72 %) 4/4 (50/50 %) 1/9 (10/90 %) 0.088
AFND 6 (33 %) 2 (25 %) 4 (40 %) NS
DIND 8 (44 %) 5 (62 %) 3 (33 %) NS
Hunt and Hess grade 3 [1–5] 3 [1–4] 3.5 [1–5] NS
WFNS grade 3 [1–5] 3 [1–5] 3.5 [1–5] NS
Grade I 4 (22.2 %) 1 (12.5 %) 3 (30 %)
Grade II 4 (22.2 %) 3 (37.5 %) 1 (10 %)
Grade III 1 (6 %) 0 (0 %) 1 (10 %)
Grade IV 6 (33.3 %) 3 (37.5 %) 3 (30 %)
Grade V 2 (16.7 %) 1 (12.5 %) 2 (20 %)
Fisher score 3 [1–4] 3 [1–4] 3[3–3]
Extended Glasgow outcome score (EGOS) after 180 days 2 [0–7] 2 [0–7] 1 [0–7]
Modified ranking scale after 15 days 5 [0–6] 5 [0–6] 5 [3–6] NS
Mortality 180 days 6 (33.3 %) 2 (25 %) 4 (40 %) NS
Duration of mechanical ventilation (hrs) 226 [33–357] 268 [63–331] 178 [0–357] NS
Data are expressed as median [min–max] or as absolute numbers
AFND acute focal neurological deficit, DIND delayed ischemic neurological deficit, WFNS World Federation of Neurological Surgeons
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differences between patients with and without pneumonia.
The median duration of mechanical ventilation was less in
patients with pneumonia, though this difference did not
reach significance.
Cerebral Metabolism
Levels of cerebral glucose, pyruvate, and glycerol were
comparable between patients with/without AFND, DIND, and
bacterial pneumonia in this patient population. The lactate/
pyruvate ratio (LPR) appeared to be elevated in DIND patients
(days 5–7), but reached no significant difference (Fig. 2). The
time pattern of lactate elevations in patient with pneumonia
and DIND matched the timing of their respective onset days,
while levels of lactate in patients with/without AFND were
comparable.
Cerebral Lactate
Mean cerebral lactate levels were elevated at day 3 in patients
with bacterial pneumonia (n =9, median=6.82 mmol/L) vs.
patient without bacterial pneumonia (n =6, median=
2.90 mmol/L). Intergroup difference (Mann–Whitney U test)
was significant p =0.036 (Fig. 2). Lactate at day 7 was signif-
icantly higher in patients fulfilling criteria for DIND (n =6,
median=8.16mmol/l) compared to neurologically asymptom-
atic patients (n =10, median=5.85 mmol/l, p <0.05, Fig. 3).
Comparisons of Adverse Event's Onsets and Peaks
of the Lactate Levels
The onset of pneumonia was at median 2.5 days (60 h,
range 24–192 h) after aSAH onset. To compare timing
of lactate peaks and more detailed pneumonia onset, we
used hourly measured values. Significantly elevated
Table 2 Patient characteristics for DIND
All patients (n=18) No DIND (n =10) DIND (n =8) p Value
Age 51.5 [31–77] 49 [31–68] 54 [36–77] NS
Male/female 8/10 (55/45 %) 4/6 (40/60 %) 4/4 (50/50 %) NS
Coiling/clipping 5/13 (28/72 %) 3/7 (30/70 %) 2/6 (25/75 %) NS
AFND 6 (33 %) 2 (25 %) 4 (40 %) NS
Hunt and Hess grade 3 [1–5] 3 (1–5) 3.5 (2–4) NS
WFNS grade 3 [1–5] 2 (1–5) 4 (1–5) NS
Grade I 4 (22.2 %) 3 (37.5 %) 1 (10 %)
Grade II 4 (22.2 %) 2 (25 %) 2 (20 %)
Grade III 1 (6 %) 0 (0 %) 1 (10 %)
Grade IV 6 (33.3 %) 1 (12.5 %) 5 (50 %)
Grade V 2 (16.7 %) 2 (25 %) 1 (10 %)
Fisher score 3 [1–4] 3 [1–4] 3 [3–4] NS
Extended Glasgow outcome score (EGOS) after 180 days 2 [0–7] 4 [0–7] 1 [0–7] NS
Modified ranking scale after 15 days 5 [0–6] 5 [0–6] 5 [1–6] NS
Mortality 180 days 6 (33.3 %) 2 (25 %) 4 (40 %) NS
Duration of mechanical ventilation (h) 226 [33–357] 239 [33–331] 307 [80–357] NS
Data are expressed as median [min–max] or as absolute numbers
AFND acute focal neurological deficit, DIND delayed ischemic neurological deficit, WFNS World Federation of Neurological Surgeons
Fig. 1 Time course of adverse events. Six patients (33 %) presented
acute focal neurological deficits (AFNDs). Ten patients (56 %) suffered
from early onset pneumonia (onset day median=2.5; range=1–4). Eight
patients (45 %) developed DIND (onset day median=7; range=5–15)
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lactate levels have been found at median 84 h, range 42–139 h
after aSAH. The early peak of lactate levels was within 61–
72 h after aSAH onset, meeting the median of pneumonia
onset perfectly. DINDwas diagnosed at median day 7 (median
168 h, range 120–360 h) after aSAH onset, having significant
higher lactate levels at similar time (median 150 h; range 128–
199).
Multivariate Analysis
Multivariate analysis for levels of lactate (days 2–4) was
calculated for multiple factors as independent variables: pneu-
monia no /yes ,Hunt and Hess grade low /high , AFND no /yes ,
and coiling vs clipping . Levene's tests of equality of error
variances were performed firstly for each day to test the
assumption of MANOVA that the variances of each variable
are equal across the groups.
The tests were not significant, indicating that differ-
ence of variances in MANOVA can be interpreted. It
turned out that pneumonia was the only significant
factor. All other independent factors included in the
model were not able to explain the variance of lactate
levels at the relevant days. Pillai's trace-based p value
was significant (F value=7.33 with exact testing; partial
eta squared=0.846; p =0.042).
The same multivariate analysis has been performed for
levels of lactate at days 8–11 with factors DIND yes /no , Hunt
and Hess grade low /high , AFND no /yes , and coiling vs
clipping . Only DIND was a significant factor (F value=
249.875; partial eta squared=0.996; p =0.040), while all other
independent variables included in the model failed to explain
differences in variance of lactate levels.
Receiver Operation Characteristic
To determine cut-off values of cerebral lactate predicting
pneumonia, and DIND, a ROC analysis was carried out. For
pneumonia at day 3, the area under curve (AUC) was 0.833
with p =0.034. The optimum cut-off point to predict
pneumonia was 3.57 mmol/L with a sensitivity of 0.77
and a specificity of 0.66. Cerebral lactate >6.28 mmol/L
at day 8 turned out to be also predictive for DIND
(AUC=0.875; sensitivity/specificity=0.75/0.62 %; p =
0.042). Positive and negative predictive values have not been
calculated due to small sample size. Lactate failed to be
predictive for mortality during monitoring (until day 15),
and follow up (day 180).
Discussion
The aim of the present study was to measure parameters of
cerebral metabolism in the ECF of aSAH patients and to
Fig. 3 Time course of cerebral lactate in patients with DIND. Lactate at
day 7 (peak hour 145–156 after onset) was significant (*p <0.05) higher
in patients fulfilling criteria for DIND (squares n =6, median=
8.16 mmol/l) compared to neurologically asymptomatic patients (circles
n =10, median=5.85 mmol/l). Values are given as means; ±1 SD. SD
standard deviation
Fig. 2 Time course of cerebral lactate in aSAH patients with pneumonia.
Lactate was elevated at day 3 (peak 61–72 h after onset) in patients with
infections (squares, n =9, median=6.82 mmol/L) vs. patient without
infections (circles, n =6, median=2.90 mmol/L). Values are given as
means; ±1 SD. SD, standard deviation.*Intergroup difference in Mann–
Whitney U test was significant (p =0.036)
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evaluate its potential value reflecting primary aSAH severity
and occurrence of infection development, mainly bacte-
rial pneumonia. To our knowledge, this study is the first
detailed investigation on cerebral interstitial energy me-
tabolism in aSAH patients in relation to infection. The
idea behind it is that the primary damage may initiate
inflammatory processes leading to a depressed immune
status and more likely infections after aSAH.
Brain Metabolism
Cerebral MD provides information on the metabolic state of the
injured brain, and it permits to determine a variety of markers of
immunocompetence in the cerebral ECF [26]. This is of rele-
vance since both the blood–brain and blood–CSF barriers may
be variably disrupted following aSAH, rendering blood and
CSF levels of such markers less reliable [27]. Our most inter-
esting finding is that early elevated lactate levels in ECF corre-
lated in univariate and multivariate analysis with occurrence of
bacterial pneumonia, while late elevations correlated with
DIND after aSAH. The causality of elevated cerebral lactate
in patients with pneumonia remains unclear; besides being a
marker of the severity of compromised cerebral tissue after
aSAH, systemic hypoxemia, or lactatemia with damaged blood
brain barrier are possible explanations for high-cerebral lactate
levels. Our second finding, that a second peak of cerebral lactate
is related to the occurrence of DIND confirms previous data by
others [28] and our group [22]. These studies have identified
cerebral lactate as well as the lactate/pyruvate ratio to be pre-
dictive for cerebral ischemia in aSAH patients [28, 29].
This is in line with our results concerning the lactate/
pyruvate ratio which appeared to be elevated in DIND patients
in the same time period (days 5–7), but reached no significant
difference probably due to interindividual variability, low-
sample size, and the grade of ischemia present in these patients
(Fig. 4).
Aneurysmal SAH-Induced Bacterial Pneumonia
Bacterial pneumonia is not only the leading cause of severe
sepsis in ICU patients and the most common cause of death in
stroke patients, but also a well-known complication in aSAH
[2, 3, 6]. The high incidences of abnormal mental status,
reduction of bulbar reflexes, dysphagia, and aspiration or me-
chanical ventilation for several days are considered to be major
contributors to the high incidence of bacterial pneumonia after
stroke [30]. It is therefore not surprising that this com-
plication is frequent in high-grade SAH patients (WFNS
grade IV–V) [6]. Experimental and clinical studies stress
the role of immunocompetence and suggest that dysphagia is a
confounder rather than the sole reason for nosocomial infec-
tions [4, 5]. This is supported by experimental findings in the
mouse model of transient middle cerebral artery occlusion,
demonstrating that even 14 days after cerebral ischemia intra-
nasal application of only 200 colony-forming units of Strepto-
coccus pneumoniae was sufficient to cause severe pneumonia
and bacteremia in stroke animals, while in contrast, 200,000
colony-forming units were needed to induce pneumonia of
similar severity in sham-operated animals [31]. This means that
otherwise harmless minor bacterial aspiration leads to severe
pneumonia and bacteremia after ischemic stroke suggesting
that the deleterious combination of stroke-induced immunode-
ficiency with stroke-facilitated aspiration dramatically increases
the susceptibility to infection. Thus, immunodepression after
acute CNS injury appears to be an important risk factor for the
development of infectious complications and outcomes.
A major limitation to our study is the small number of
patients. Furthermore, SAH is a heterogeneous disease limit-
ing the generalization of our results. These patients are com-
monly intubated and at high risk for aspiration, pulmonary
edema, and fluid overload, all of which increase the chances
of pneumonia [32]. Interestingly, in our study population, the
median duration of mechanical ventilation was comparable in
patients with and without pneumonia.
Fig. 4 Time course of the lactate/
pyruvate ratio (LPR) after aSAH.
After a short peak of the LPR in
no-DIND-patients (day1)—
possibly an insertion effect—
levels appeared to be higher in
DIND patients (NS)
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Microdialysis is a local monitor of cerebral metabolism and
results cannot be generalized for the whole brain. Neverthe-
less, due to the time and cost intensive nature of microdialysis,
only a few data are available in prospective studies in aSAH
patients. The technique can detect harmful secondary insults,
and may be used as end points for goal-directed therapy, with
the aim of creating an optimal physiological environment for
the comatose-injured brain [32]. A higher patient number
would allow more substantial analysis to confirm that early
lactate levels (day 3) serve as predictor of pneumonia. This
might support the hypothesis that early primary brain damage
due to an aSAH, reflected in high-lactate levels, initiates
inflammatory processes and immunosuppression—followed
by bacterial infections later on.
Conclusion
Early elevated lactate levels in ECF were correlated with
occurrence of bacterial pneumonia, while late elevations cor-
related with DIND after aSAH. The causality of elevated
lactate remains unclear in patients with pneumonia: a systemic
hypoxemia or lactatemia with damaged blood brain barrier are
possible reasons. Thus, in a next step, a more comprehensive
analysis will be performed to elucidate possible relationships
between MD markers and markers of immunocompetence.
MD may help to identify aSAH patients at risk for severe
infections, probably profiting from earlier therapy.
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